Literature DB >> 21868507

Tuberculosis drug development: ensuring people living with HIV are not left behind.

Anne F Luetkemeyer1, Haileyesus Getahun, Gabriel Chamie, Christian Lienhardt, Diane V Havlir.   

Abstract

An unprecedented number of new tuberculosis (TB) medications are currently in development, and there will be great pressure to deploy these new drugs among all populations after their efficacy is demonstrated. People living with HIV experience a large burden of TB and have a particularly pressing need for TB treatments that are shorter and less toxic. In addition, all people living with HIV now require antiretroviral therapy during TB treatment. A roadmap of the research, programmatic, and regulatory considerations includes the following: (1) inclusion of people living with HIV early in clinical trials for treatment and prevention using new TB medications, (2) prioritization of key studies of HIV-TB drug interactions and interactions between new TB agents, and (3) optimization of clinical trial infrastructure, laboratory capacity, and drug susceptibility testing.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21868507      PMCID： PMC3361323          DOI： 10.1164/rccm.201106-0995PP

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


  47 in total

1.  Biomarkers for tuberculosis disease activity, cure, and relapse.

Authors:  Robert S Wallis; Cunshan Wang; T Mark Doherty; Phillip Onyebujoh; Mahnaz Vahedi; Hannu Laang; Ole Olesen; Shreemanta Parida; Alimuddin Zumla
Journal:  Lancet Infect Dis       Date:  2010-02       Impact factor: 25.071

Review 2.  Running a tightrope: regulatory challenges in the development of antiretrovirals.

Authors:  Lisa K Naeger; Kimberly A Struble; Jeffrey S Murray; Debra B Birnkrant
Journal:  Antiviral Res       Date:  2009-08-07       Impact factor: 5.970

Review 3.  New approaches and emerging technologies in the diagnosis of childhood tuberculosis.

Authors:  Ben J Marais; Madhukar Pai
Journal:  Paediatr Respir Rev       Date:  2007-06-05       Impact factor: 2.726

4.  HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality.

Authors:  Neel R Gandhi; N Sarita Shah; Jason R Andrews; Venanzio Vella; Anthony P Moll; Michelle Scott; Darren Weissman; Claudio Marra; Umesh G Lalloo; Gerald H Friedland
Journal:  Am J Respir Crit Care Med       Date:  2009-10-15       Impact factor: 21.405

5.  Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.

Authors:  Andrew Boulle; Gilles Van Cutsem; Karen Cohen; Katherine Hilderbrand; Shaheed Mathee; Musaed Abrahams; Eric Goemaere; David Coetzee; Gary Maartens
Journal:  JAMA       Date:  2008-08-06       Impact factor: 56.272

6.  Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

Authors:  Susan E Dorman; John L Johnson; Stefan Goldberg; Grace Muzanye; Nesri Padayatchi; Lorna Bozeman; Charles M Heilig; John Bernardo; Shurjeel Choudhri; Jacques H Grosset; Elizabeth Guy; Priya Guyadeen; Maria Corazon Leus; Gina Maltas; Dick Menzies; Eric L Nuermberger; Margarita Villarino; Andrew Vernon; Richard E Chaisson
Journal:  Am J Respir Crit Care Med       Date:  2009-04-30       Impact factor: 21.405

7.  A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.

Authors:  R Rustomjee; C Lienhardt; T Kanyok; G R Davies; J Levin; T Mthiyane; C Reddy; A W Sturm; F A Sirgel; J Allen; D J Coleman; B Fourie; D A Mitchison
Journal:  Int J Tuberc Lung Dis       Date:  2008-02       Impact factor: 2.373

8.  Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis.

Authors:  Karen Cohen; Gilles van Cutsem; Andrew Boulle; Helen McIlleron; Eric Goemaere; Peter J Smith; Gary Maartens
Journal:  J Antimicrob Chemother       Date:  2007-12-19       Impact factor: 5.790

9.  Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis.

Authors:  R Rustomjee; A H Diacon; J Allen; A Venter; C Reddy; R F Patientia; T C P Mthiyane; T De Marez; R van Heeswijk; R Kerstens; A Koul; K De Beule; P R Donald; D F McNeeley
Journal:  Antimicrob Agents Chemother       Date:  2008-05-27       Impact factor: 5.191

10.  Building clinical trials capacity for tuberculosis drugs in high-burden countries.

Authors:  Neil Schluger; Unni Karunakara; Christian Lienhardt; Thomas Nyirenda; Richard Chaisson
Journal:  PLoS Med       Date:  2007-11-06       Impact factor: 11.069
View more
  3 in total

Review 1.  Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa.

Authors:  Stephen D Lawn; Anthony D Harries; Graeme Meintjes; Haileyesus Getahun; Diane V Havlir; Robin Wood
Journal:  AIDS       Date:  2012-11-13       Impact factor: 4.177

Review 2.  Use of anti-retroviral therapy in tuberculosis patients on second-line anti-TB regimens: a systematic review.

Authors:  Matthew Arentz; Patricia Pavlinac; Michael E Kimerling; David J Horne; Dennis Falzon; Holger J Schünemann; Sarah Royce; Keertan Dheda; Judd L Walson
Journal:  PLoS One       Date:  2012-11-05       Impact factor: 3.240

3.  Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons.

Authors:  Amita Gupta; Michael D Hughes; Anthony J Garcia-Prats; Katherine McIntire; Anneke C Hesseling
Journal:  PLoS Med       Date:  2019-08-15       Impact factor: 11.069
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.